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after neoadjuvant chemoradiation: a cohort
study from a tertiary referral hospital
Christian Galata1*, Kirsten Merx2, Sabine Mai3, Timo Gaiser4, Frederik Wenz3, Stefan Post1, Peter Kienle6,
Ralf-Dieter Hofheinz2 and Karoline Horisberger1,5
Abstract
Background: To investigate the importance of adjuvant chemotherapy in locally advanced rectal cancer (≥ cT3 or N+)
staged ypT0–2 ypN0 on final histological work-up after neoadjuvant chemoradiation and radical resection.
Methods: The clinical course of patients with rectal cancer and ypT0–2 ypN0 stages after neoadjuvant chemoradiation
and radical resection was analyzed from 1999 to 2012. Patients were divided into two groups depending on whether
adjuvant chemotherapy was administered or not. Overall survival, distant metastases, and local recurrence were
compared between both groups.
Results: Fifty-four patients with adjuvant (ACT) and 50 patients without adjuvant chemotherapy (NACT) after
neoadjuvant chemoradiation followed by radical resection for rectal cancer were included in the analysis. Mean
follow-up was 68 ± 33.7 months. One patient without adjuvant chemotherapy and none in the ACT group
developed a local recurrence. Five patients in the NACT group and three patients in the ACT group had distant
recurrences. Median disease-free survival for all patients was 65.5 ± 34.5 months. Multivariate analysis showed
adjuvant chemotherapy to be the most relevant factor for disease-free and overall survival. Patients staged ypT2
ypN0 showed a significantly better disease-free survival after application of adjuvant chemotherapy. Disease-free
survival in ypT0–1 ypN0 patients showed no correlation to the administration of adjuvant chemotherapy.
Conclusion: Administration of adjuvant chemotherapy after neoadjuvant chemoradiation and radical resection in
rectal cancer improved disease-free and overall survival of patients with ypT0–2 ypN0 tumor stages in our study.
In particular, ypT2 ypN0 patients seem to profit from adjuvant treatment.
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Background
Neoadjuvant chemoradiation is a considered standard
treatment for locally advanced rectal cancer [1]. Current
guidelines for the treatment of colorectal cancer in
Germany recommend the administration of adjuvant
chemotherapy for all rectal cancer patients after neoadju-
vant chemoradiation and total mesorectal excision (TME),
regardless of the postoperative pathologic staging result
[2]. This recommendation is based on the CAO/ARO/
AIO-94 and FFCD 9203 studies [1, 3]. However, hard evi-
dence is lacking, especially for patients staged ypT0–2
ypN0. While an exploratory analysis suggested that par-
ticular patients with good response (ypT0–2) benefit from
adjuvant chemotherapy [4] randomized controlled trials
addressing the same question showed no benefit for adju-
vant chemotherapy [5, 6]. However, these trials have rele-
vant methodological restrictions. While a recent pooled
analysis showed positive effects for adjuvant chemother-
apy, another recent meta-analysis failed to do so [7, 8].
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In adherence to the German national guidelines from
before 2008, ypT0–2 ypN0 patients were then not
treated with postoperative chemotherapy (NACT) at our
institution. After the introduction of the amended guide-
lines in 2008, adjuvant treatment was routinely adminis-
tered to the same group of patients (ACT). In the
present study, we investigated patients with locally ad-
vanced rectal cancer in clinical staging (UICC stages II
and III) treated with neoadjuvant chemoradiation and
TME and then staged ypT0–2 ypN0. On the basis of a
prospectively maintained database, the oncologic out-
comes of these patients were analyzed.
Methods
Ethics approval
The institutional review board reviewed and approved
the protocol; the study was conducted in accordance
with the Declaration of Helsinki.
Patient selection
All surgically treated colorectal carcinomas at the Depart-
ment of Surgery, University Hospital Mannheim,
Germany, between 1999 and 2012 were retrospectively an-
alyzed on the basis of prospective databases. Patients with
locally advanced rectal cancer who underwent neoadju-
vant chemoradiation and subsequent TME in curative in-
tent were eligible for the study when diagnosed ypT0–2
ypN0 in postoperative pathological staging. Exclusion cri-
teria were postoperative death (in-hospital mortality),
UICC stage IV and recurrent disease, or missing informa-
tion on whether adjuvant chemotherapy was adminis-
tered. Primary outcome measure was disease-free survival
(DFS). Disease was defined as the event of local and/or
distant recurrence during follow-up. DFS was defined as
absence of local and/or distant recurrence and death by
any cause during follow-up after primary hospital stay.
Pre-treatment evaluation
The presence of adenocarcinoma was confirmed by
pathological examination in all cases. Clinical staging
was performed using rigid rectoscopy, endorectal ultra-
sound, radiographic imaging of the chest, and abdominal
ultrasound. Routine performance of magnetic resonance
imaging (MRI) of the pelvis was introduced in 2003.
Computed tomography (CT) scans of the thorax and/or
abdomen were obtained in the majority of cases.
Preoperative chemoradiation and surgery
Neoadjuvant chemoradiation was administered when lo-
cally advanced rectal cancer was diagnosed (uT3-4, uN+).
As preoperative chemotherapy regimen, capecitabine,
capecitabine + irinotecan (XELIRI), XELIRI + cetuximab,
capecitabine + oxaliplatin (XELOX), intravenous 5-FU, or
panitumumab were used. Radiation therapy was applied
as external-beam radiation with a target dose of 50.4 Gy.
TME was scheduled 4 to 5 weeks after completing neoad-
juvant chemoradiation before 2008, and 8 to 12 weeks
after completion of chemoradiation for patients from
2008 till 2012.
Pathology investigation
Resected specimens were fixated in formalin and patho-
logical work-up was done according to published stan-
dards [9]. If no residual tumor was apparent, the initial
tumor-bearing area was sliced and embedded. Tumor re-
gression grade was determined based on the classifica-
tion proposed by the Japanese Society for Cancer of the
Colon and Rectum (JSCCR) [10].
Postoperative chemotherapy
According to national colorectal cancer guidelines before
the year 2008, patients were not offered postoperative
chemotherapy when diagnosed ypT0–2 ypN0 in final
pathological staging. After 2008, adjuvant chemotherapy
became the treatment of choice for those patients when no
contraindications were present. For adjuvant chemotherapy
capecitabine, XELOX or intravenous 5-FU was used.
Statistical analysis
Baseline characteristics of all patients together were
evaluated with respect to their influence on outcome.
The characteristics were then compared between pa-
tients who received adjuvant chemotherapy and those
who did not. Comparisons of frequencies between the
two groups were performed using the Student’s t test or
the chi-square test. Differences of non-parametric quan-
titative data were analyzed using the Mann-Whitney U
test. Kaplan-Meier estimates were computed for recur-
rence and survival and were compared between the
two treatment groups using the log-rank test. A p
value < 0.05 was considered statistically significant. All
calculations were made with the SPSS version 22.0
(IBM© SPSS® Statistics).
Results
Patients’ characteristics
Initial screening of the database returned 131 patients
staged ypT0–2 ypN0 rectal cancer between 1999 and
2012 out of 397 patients who had received neoadjuvant
treatment. Twenty-seven patients were excluded due to
the above mentioned exclusion criteria. A total of 104
patients met the inclusion criteria, 28 females (26.9%)
and 76 males (73.1%) with a mean age of 62.0 ±
10.7 years. Low rectal cancer was present in 48 patients
(46.2%); 52 patients (50%) had cancers of the mid rec-
tum, and 4 patients (3.8%) of the upper rectum. Median
dose of delivered radiation was 50.4 Gy (range 36 to
50.4 Gy). Sphincter-preserving operation was performed
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in 79.8% of the patients (n = 83). Postoperative chemother-
apy was given to 54 patients (51.9%), while 50 patients
(48.1%) did not receive adjuvant treatment. Ten of the pa-
tients (18.5%) who had received adjuvant therapy had sur-
gery before 2008. In the group without adjuvant therapy,
41 patients (82%) were operated before 2008.
Data on gender, age, tumor height, preoperative radi-
ation dose, and type of operation did not differ signifi-
cantly between ACT and NACT (Table 1). A total of 46
patients (44.2%) were diagnosed ypT0 or ypT1 whereas
58 patients (55.8%) were diagnosed ypT2 in the final
pathological examination. Distribution of ypT0, T1, and
T2 showed a non-significant trend towards a higher rate
of ypT0 in the patient group that received no adjuvant
treatment (Table 1). Patients with ypT0–1 versus ypT2
showed no difference between the treatment groups.
Neither the distribution of tumor regression grading nor
the number of retrieved lymph nodes showed differences
between both groups.
Oncologic outcomes according to adjuvant chemotherapy
Mean follow-up was 68.0 months (± 33.7) for all patients
eligible for the study. Follow-up time was significantly
longer in the group without adjuvant chemotherapy
(p < 0.005; Table 2). Mean disease-free survival was
65.5 ± 34.5 months. Overall recurrence of the disease
was seen in nine patients (8.7%). Metachronous metastasis
occurred in eight cases (7.7%) and locoregional recurrence
in one patient (0.96%).
In the univariate analysis, age, sex, tumor height, and
extirpation had no influence on disease-free survival.
Log-rank tests showed that adjuvant chemotherapy had
no influence on local recurrence (p = 0.382), distant me-
tastasis (p = 0.54), or overall recurrence (p = 0.382) but
on disease-free survival (p = 0.037) and overall survival
(p = 0.017) (Fig. 1). The 3-year OS and DFS were 98 and
94% in the ACT group, respectively, and 87 and 86% in
the NACT group.
Anastomotic leakage showed a statistical trend to-
wards influencing overall (p = 0.053) but not disease-free
survival (p = 0.435). Adjuvant chemotherapy, after strati-
fication for anastomotic leakage, demonstrated a statisti-
cally significant effect on disease-free survival in patients
without leakage (p = 0.016); however, there was no sig-
nificant influence of adjuvant chemotherapy on
disease-free survival in patients with anastomotic leakage
(p = 0.293).
ypT stages did not influence disease-free survival (p =
0.513), and also ypT stage groups (ypT0–1 versus ypT2)
were not correlated to disease-free survival (p = 0.265)
(Fig. 2). After stratification along these groups, no sig-
nificant correlation with adjuvant chemotherapy could
Table 1 Patient characteristics of patients without and with adjuvant chemotherapy. In one patient, regression grade could not be
determined
No adjuvant therapy (n = 50) Adjuvant therapy (n = 54) p value
Age 62.9 ± 11.6 61.2 ± 9.8 0.414
Sex (female/male) 36/14 40/14 0.829
Abdominoperineal resection 10/50 11/54 1.0
Anastomotic leakage 9/40 3/43 0.062
T stage
ypT0 20 (40%) 12 (22%) 0.064
ypT1 6 (12%) 8 (15%)
ypT2 24 (48%) 34 (63%)
T stage
ypT0–1 26 20 0.167
ypT2 24 34
Lymph nodes retrieved 13.1 ± 0.7 13.5 ± 0.7 0.687
Lymph nodes
< 12 12 (24%) 12 (22.2%) 1.0
≥ 12 38 (76%) 42(77.8%)
Regression grade (JSCCR)
TRG 0 0 1 (2%) 0.384
TRG 1 11 (22%) 9 (17%)
TRG 2 20 (49%) 32 (60%)
TRG 3 (pCR) 18 (36%) 12 (22%)
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be seen concerning disease-free survival in ypT0–1 (p =
0.556); however, ypT2 patients showed a significantly
better disease-free survival after adjuvant chemotherapy
(p = 0.014) (Fig. 3). In ypT0 (p = 0.195) and ypT1 (p =
0.386), no correlation between adjuvant chemotherapy
and disease-free survival could be detected. After stratifi-
cation in groups of pCR (pathological complete re-
sponse) versus ypT1–2, disease-free survival showed no
significant correlation to adjuvant treatment in ypT0 pa-
tients (p = 0.195), and only marginally in ypT1–2 pa-
tients (p = 0.056). The 3-year DFS and OS in the ACT
group were both 100% in ypT0, 100 and 88% in ypT1,
and 94 and 100% in ypT2, respectively, and in the
NACT group both 90% in ypT0, both 100% in ypT1, and
79 and 82% in ypT2.
When patients were classified in groups with more or
less than 12 lymph nodes harvested, the number of
lymph nodes harvested did not influence the disease-free
survival by itself (p = 0.821). The interaction of lymph
nodes harvested and adjuvant chemotherapy showed a
significantly better disease-free survival in patients with
more than 12 lymph nodes (p = 0.009) but no significant
influence of adjuvant chemotherapy in patients with less
than 12 lymph nodes (p = 0.809).
Of the patients, 90% had at least half of the indicated
chemotherapy cycles, 83% had 5 or 6 chemotherapy cy-
cles, and 7% had 3 or 4 cycles (Table 3). Completeness
of chemotherapy had no influence on the outcome.
Discussion
Introduction of neoadjuvant chemoradiation for rectal
adenocarcinoma has in combination with TME surgery
led to reduce rates of locoregional recurrence [1]. This
improvement of local control, however, did not result
in prolonged overall survival [11]. Our data show a
significant benefit from adjuvant treatment for
disease-free and overall survival but no benefits with
respect to recurrence.
Adjuvant chemotherapy after neoadjuvant treatment
and TME surgery is administered with the intention of
reducing the incidence of distant metastasis and thereby
improving survival. Although this has been prospectively
investigated in several trials, controversy remains [5, 6].
In the just recently published study by Breugom et al.,
Table 2 Follow-up, local, and distant recurrence in patients without and with adjuvant chemotherapy
No adjuvant therapy (n = 50) Adjuvant therapy (n = 54) p value
Follow-up (months) 82.2 ± 38.7 54.7 ± 21.4 0.003
Local recurrence 1 0 0.481
Distant recurrence 5 3 0.477
Fig. 1 DFS in all patients with respect to adjuvant chemotherapy
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patients with ypTNM stage 0 or I were explicitly ex-
cluded which was also criticized [8, 12, 13]. A
meta-analysis identified this subgroup to profit the most
from adjuvant chemotherapy [14]. Maas et al. found the
most pronounced effect of adjuvant chemotherapy on
disease-free survival in ypT1–2 patients both in com-
parison to higher stages but also to pCR patients [7].
Our analysis found the most pronounced effect of adju-
vant chemotherapy in ypT2 patients. The theoretical
consideration that tumors with the combination of
Fig. 2 DFS in all patients with respect to T-stage groups (ypT0–1 ypN0 versus ypT2 ypN0)
Fig. 3 DFS in ypT2 ypN0 patients with respect to adjuvant chemotherapy
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responsiveness (shown by downstaging) and continued
considerable risk for local and distant recurrence (> ypT1)
would profit from adjuvant treatment might in particular
hold true for ypT2 [4].
Another restriction in the analysis of Breugom et al. is
that the majority of the patients received bolus 5-FU [8].
However, an explanatory phase III trial showed better
disease-free survival after perioperative treatment with
capecitabine than with 5-FU [15]. In our analysis, only
two patients received 5-FU postoperatively; therefore, a
comparison of the effect of the two agents cannot be
undertaken.
Our results are in conflict with the EORTC 22921
study that previously reported ypT1–2 patients to bene-
fit from postoperative chemotherapy after 5 years; how-
ever, recently published late results after 10 years
showed no improvement in disease-free or overall sur-
vival [4, 16]. Meta-analyses presented inherently contra-
dictory results with respect to the positive effects of
adjuvant chemotherapy on disease-free and overall sur-
vival [7, 8, 17, 18]. However, it is difficult to draw con-
clusions from these meta-analyses as the included
studies have relevant shortcomings. As mentioned
above, TME was not mandatory in some of the trials;
others revealed a questionable quality of surgery with a
R1 rate above 10% and finally, but most important, many
of the studies showed a high percentage of patients not
undergoing any adjuvant chemotherapy or not the ini-
tially planned number of cycles [5]. Low adherence to
planned postoperative chemotherapy is one of the major
problems of the available randomized trials, and it is a
serious problem for interpretation of non-significant re-
sults as a proof for ineffectiveness of adjuvant chemo-
therapy [6, 8, 19]. In the EORTC 22921 trial, only 41%
of the patients received complete chemotherapy [13, 16].
Anastomotic leakage is a major problem for patients
who actually would have been eligible for adjuvant ther-
apy. In our cohort, anastomotic leakage showed a trend
towards negatively influencing application of adjuvant
chemotherapy (p = 0.062). This is well in accord with
general clinical experience that anastomotic leakage
often prevents application of chemotherapy.
The results of the PROCTOR-SCRIPT trial challenge
our study, as this is the first randomized trial on the ap-
plication of adjuvant chemotherapy in neoadjuvantly
treated patients with rectal cancer [6]. In this study, no
benefit from adjuvant chemotherapy could be detected.
However, again, there are limitations in this study. The
trial had to be closed earlier due to poor patient recruit-
ment and survival was better than expected suggesting
that the trial was probably underpowered. In the PROC-
TOR part of the trial, only 50% of the patients had a CT
or MRI scan before treatment, so inaccuracy of staging is
probably a major bias. Patients were preoperatively treated
either with 5 × 5 Gy or with long-term chemoradiation;
however, the longstanding oncological results of a ran-
domized comparison of these two therapy schedules are
still awaited [20]. Furthermore, stagewise analysis was not
performed in the PROCTOR-SCRIPT trial and the num-
ber of retrieved lymph nodes not reported [6].
The question if the number of lymph nodes retrieved
during surgery would influence long-term outcome re-
spectively the application of chemotherapy and thereby
the outcome has to be addressed. Most guidelines rec-
ommend investigation of at least 12 lymph nodes for de-
termining final pathologic tumor stage [21]. In several
studies, the number of detected locoregional lymph
nodes was decreased after neoadjuvant chemoradiation
[22, 23]. However, when < 12 lymph nodes are investi-
gated, metastasis could be missed and histopathological
stage underestimated. As performance of adjuvant treat-
ment is stage-dependent also patients that would need
therapy are then excluded. When intensified pathology
work-up of the specimens is performed and more lymph
nodes are evaluated, the number of metastatic lymph
nodes may raise thereby possibly resulting in stage mi-
gration (“Will Rogers phenomenon”) [24]. While some
studies indicate an association between the number of
harvested lymph nodes and oncologic outcome [24], the
same authors could not reproduce these results when
neoadjuvant chemoradiation was administered [25]. Re-
cent studies on this topic continue to give conflicting re-
sults; therefore, the significance of retrieving more than
12 lymph nodes remains unclear [26, 27]. In the present
study, retrieval of less than 12 lymph nodes showed no
influence of adjuvant chemotherapy with respect to
disease-free survival, while more than 12 lymph nodes
and adjuvant chemotherapy were correlated to a better
disease-free survival.
There are several limitations to our study. First, this is a
retrospective study. Patients were not prospectively ran-
domized and selection bias cannot be excluded, even
though the groups were well matched in size, age, gender,
and tumor-specific parameters. As the indication for adju-
vant therapy changed in 2008 in Germany, the compari-
son could be described as historical. Second, follow-up
time was significantly longer in the NACT group. The dif-
ference is explainable by the consecutive change of guide-
lines. These two points in turn can be regarded as
strength of this study, making it a “quasi-RCT.” Further-
more, follow-up in patients who received adjuvant chemo-
therapy still was 54 months in mean.
Table 3 Completion of adjuvant chemotherapy (in three
patients, the number of cycles could not be clarified anymore)
Completeness of chemotherapy 5–6 cycles 3–4 cycles 1–2 cycles
ACT group (n = 54) 45 (83%) 4 (7%) 2 (4%)
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Third, a possible sign of selection bias is the higher
proportion of ypT0 patients in the group without adju-
vant chemotherapy. In fact, clinicians are often averse to
the application of adjuvant chemotherapy in pCR pa-
tients. Breugom et al. criticized the retrospective char-
acter of the study by Maas et al. and the fact that the
other study supporting adjuvant chemotherapy was a
meta-analysis [7, 14, 28]. However, a meta-analysis
usually reduces the risk of confounding.
A more detailed analysis of surgical complications other
than anastomotic leakage could not be performed. Even if
the database was prospectively performed and updated, the
number of parameters documenter increased over time,
e.g., the Clavien-Dindo complication grading was only in-
troduced at a later stage. However, anastomotic leakage,
which was adequately documented in the database, is one
of the most severe complications in rectal surgery and most
often the reason why adjuvant chemotherapy is delayed or
not started at all. Moreover, leakage has been shown to in-
fluence the oncological outcome, and as both groups dem-
onstrated a comparable leakage rate, this factor can be
ruled out as a biasing factor.
At last, the sample size is too small to be able to evalu-
ate statistical significant difference in rare incidences
such as local recurrence that occurred only once.
Regardless of these limitations, the results support
current guideline recommendations that in patients with
ypT0–2 tumors adjuvant chemotherapy should continue
to be administered, especially in ypT2 stages.
Conclusion
Administration of adjuvant chemotherapy after neoadju-
vant chemoradiation and radical resection in rectal can-
cer improved disease-free and overall survival of patients
with ypT0–2 ypN0 tumor stages in our study. In par-
ticular, ypT2 ypN0 patients seem to profit from adjuvant
treatment.
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